Drug intelligence / Profile preview

hYP7-PC

Development stage: Preclinical
Lead developer: National Cancer Institute
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

hYP7-PC is an experimental antibody-drug conjugate (ADC) targeting glypican-3 (GPC3), a cell-surface protein highly expressed in hepatocellular carcinoma (HCC). Developed by researchers at the National Cancer Institute (NCI), the ADC consists of the humanized monoclonal antibody hYP7 conjugated to a pyrrolobenzodiazepine (PBD) dimer payload. PBD dimers are potent DNA-alkylating agents that induce interstrand cross-links, leading to cell death. In preclinical studies, hYP7-PC demonstrated significant anti-tumor activity and induced tumor regression in multiple mouse models of liver cancer as a monotherapy.

Targets

GPC3 (Glypican-3)DNA

Beyond the preview

Go deeper on hYP7-PC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hYP7-PC.

Explore the full profile